This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
In the first half of January 2022, Dr. Sameer Parikh from Mayo, Rochester, MN, discusses the present state of affairs related to COVID-19 for those with chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL.
In this short monologue, he touches on:
- the Omicron surge
- lack of response to vaccines in many with CLL/SLL
- the need to continue to follow precautions such as masking and social distancing, even if vaccinated
- waiting for the recently authorized Evusheld, the long-acting antibody preventative, to be more available
- the reality that all CLL/SLL patients, regardless of their treatment status, are immunocompromised
It can be hard not to be discouraged, but there is a reason for hope. This surge could pass quickly. There are already very effective medications authorized or approved as described in the CDC HEALTH ADVISORY: Using Therapeutics to Prevent and Treat COVID-19 for the immunocompromised, and that they won’t always be in short supply.
Stay strong. We are all in this together.
Brian Koffman MDCM (retired) MS Ed (he, him, his)
Co-Founder, Executive VP, and Chief Medical Officer
CLL Society, Inc.